Search the Newsreel

Allison Transmission: Off-Highway Boosts Revenue, But Outlook Remains Mixed (NYSE:ALSN)

High Growth Tech Stocks in the US to Watch

The U.S. market is experiencing a significant upswing, with a 21% rise over the past year and expected 17% annual earnings growth. This article highlights high-growth tech stocks that align with these positive trends, focusing on companies with strong innovation, financial health, and market …

Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM

Pacer Advisors Inc. significantly reduced its stake in Insmed, Inc. by 53.3% in the first quarter, now holding 7,279 shares valued at $1.19 million. Despite this, other major institutions like Vanguard and State Street increased their holdings, and Insmed reported strong Q2 results, exceeding …

Pix Transmissions shares surge over 12% after Q1 profit spikes 98% YoY

Allison Transmission’s Q2 Earnings Call: Our Top 5 Analyst Questions

Allison Transmission's Q2 Earnings Call: Our Top 5 Analyst Questions Allison Transmission's second quarter saw a strong positive market response, with investors reacting favorably to robust sales growth and major contract wins in the defense sector. Management attributed the revenue surge to both the …

Allison Transmission Holdings, Inc. (NYSE:ALSN) Receives Consensus Rating of "Hold" from Brokerages

Allison Transmission Holdings, Inc. (NYSE:ALSN) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $131.17 against a recent price of $118.80. Institutional investors hold 96.9% of the company's stock, with significant increases in holdings by major firms …

Pix Transmissions Q1 Results: Unaudited Financials for June 30 Quarter Approved

TransMedics Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TMDX)

TransMedics Group, Inc. (TMDX) released its Q2 2026 earnings call presentation, reporting an EPS of $0.44, which missed estimates by $0.04, and revenue of $189.95M, beating estimates by $5.96M with a 20.70% year-over-year increase. The article highlights that the presentation was published in conjunction …

TransMedics Group, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - TMDX

A class action securities lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX) on behalf of investors who suffered losses between February 28, 2023, and January 10, 2025. The lawsuit alleges that TransMedics made false statements and concealed practices such as kickbacks, fraudulent overbilling, …

Is Insmed (INSM) Cheap After Q2 Revenue Growth And Raised Guidance?

Insmed (INSM) has seen renewed investor interest after reporting a smaller net loss and raised full-year revenue guidance in its Q2 2026 earnings. The company's stock has shown strong recent gains, despite a year-to-date decline, and is considered undervalued by Simply Wall St's narrative …

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics …

Insmed (NASDAQ:INSM) Posts Earnings Results

Allison Transmission Holdings, (ALSN) Stock Forecasts

The article provides a stock forecast for Allison Transmission Holdings (ALSN), highlighting that the company is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. It notes that Allison's earnings show recovery in its core business, while acquired off-highway assets …

TransMedics Group (TMDX) Could Be 41% Undervalued As Earnings And Guidance Land

ETFs Investing in Allison Transmission Holdings, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Allison Transmission Holdings, Inc. (ALSN). It provides a detailed table including each ETF's market value, weight of ALSN stock, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV …

Insmed (INSM) Stock Cools As BRINSUPRI Surge Recasts Growth Profile

Insmed's stock experienced a slight dip despite reporting a strong biotech quarter driven by the success of BRINSUPRI, which generated $309.2 million in Q2 revenue and has full-year guidance of $1.25 billion to $1.4 billion. The company's overall quarterly revenue reached $425.5 million, significantly …

Allison Transmission Q2 Net Sales Up 92% YOY

Allison Transmission Holdings Inc. reported a significant 92% year-over-year increase in Q2 net sales, reaching $1,566 million, driven largely by the acquisition of the Allison Off-Highway business unit and growth in Defense and North American truck markets. Despite increased operating costs and a slight …

PIX Transmissions Q1FY27 profit surges 89%, led by investment gains

PIX Transmissions Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

What Insmed Stock’s Premium Is Actually Buying

Insmed (INSM) stock trades at a significant premium, 25.3 times sales, despite being 37% below its 52-week high, with this premium driven by an optimistic peak-sales estimate of over $14 billion. This estimate relies heavily on the future success of TPIP, a drug still …

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

Insmed Incorporated Stock 12‑Month Price Target Raised to $197.14, Implies 99% Upside

Insmed Incorporated's average 12-month price target has been increased to $197.14, up from $195.95, with forecasts ranging from $140 to $243 per share. This new target suggests a potential upside of approximately 99% from its August 5th closing price. The consensus rating for Insmed …

INSM|Insmed Inc|Price:134.620|Chg%:+3.520

Insmed (NASDAQ: INSM) hits $731M 2026 product revenue as losses narrow

Insmed (NASDAQ: INSM) reported a significant increase in product revenue for Q2 2026, reaching $425.5 million, and a six-month total of $731.5 million, primarily driven by the launch of BRINSUPRI and continued growth of ARIKAYCE. The company's net loss narrowed to $13.2 million for …

Insmed (INSM) Stock Looks Expensive On Sales But Strong On Returns

Insmed (INSM) stock has seen a significant surge over the past three years, yet current valuation metrics present a mixed picture. While the company's price-to-sales ratio suggests overvaluation compared to industry averages and its modeled fair value, the strong performance and anticipated success of …

TransMedics Group Inc (TMDX) Stock Up 4.9% and Still Undervalued -- GF Score: 70/100

TransMedics Group Inc (TMDX) shares rose 4.9% to $80.21, but are still estimated to be 48.7% undervalued based on its GF Value™ of $156.29. The stock holds a GF Score™ of 70/100, indicating above-average performance, particularly in growth. However, significant insider selling of $0.7 …

Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here’s What to Watch Next

Insmed (INSM) experienced a significant 33.86% surge in its share price due to a nearly fourfold increase in Q2 revenues, largely driven by its drug Brinsupri. The company's total revenues jumped 296% to $425.5 million, enabling it to slash its net loss by 96%. …

Reporting person for NASDAQ: INSM plans 27,173-share sale after prior trades

Martina Flammer, a reporting person for INSMED Inc. (NASDAQ: INSM), has filed to sell up to 27,173 shares of common stock through Merrill Lynch, with an approximate sale date of August 6, 2026. This planned sale is related to stock plan activity. The filing …

Insmed Inc Stock (INSM) Moved Up by 31.83% on Aug 6: Key Drivers Unveiled

Insmed Inc (INSM) stock surged by 31.83% due to positive clinical trial data and potential acquisition interest. Analysts have revised revenue models with an average price target of $196.74, while technical indicators suggest a sell signal and oversold conditions. The company's significant equity dilution, …

Insmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages

Insmed, Inc. (NASDAQ:INSM) has received a consensus "Buy" rating from 26 analysts, with an average 12-month price target of $209.35. Despite recent insider selling and shares trading near their 52-week low, the company reported better-than-expected quarterly earnings with revenue up 229.7% year-over-year. Analysts anticipate …

Insmed Catapults Nearly 40%, Leading A Biotech Rally

Insmed (INSM) stock surged 30% after reporting strong second-quarter sales for its new lung disease drug, Brinsupri, exceeding analyst expectations. The company also raised its full-year guidance for the drug's sales, contributing to a broader rally in the biotech sector. This positive performance helped …

FMR LLC discloses 7.4% Insmed Inc (INSM) ownership in amended 13G

FMR LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.4% in Insmed Inc (INSM), amounting to 16,127,583.08 shares of common stock. Abigail P. Johnson is also reported with beneficial ownership of the same number of shares, holding sole dispositive power …

Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks M

Earnings Flash (INSM) Insmed Incorporated Reports Q2 Revenue $425.5M, vs. FactSet Est of $393.7M

Insmed Incorporated (INSM) reported second-quarter revenue of $425.5 million, surpassing FactSet's estimate of $393.7 million. This financial update indicates a stronger-than-expected performance for the biotechnology company during the quarter. The article also notes other recent financial activities and analyst coverage related to Insmed.

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

Insmed (Nasdaq: INSM) reported strong second-quarter 2026 financial results, with total company revenues of $425.5 million. The company raised its full-year 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion and increased the peak revenue estimate for its three lead programs (BRINSUPRI, TPIP, …

INSMED Inc Q2 2026: Revenue $425.5M, EPS $(0.06) — 10-Q Summary

INSMED Inc reported strong financial results for Q2 2026, with revenue reaching $425.5M, a significant increase of 296% year-over-year. The company also narrowed its net loss to $(13.2M) and diluted EPS to $(0.06), driven by the successful commercial launch of BRINSUPRI and continued international …